GlassScriptPhysician profile
John L Falcone
NPI 1558566273
$12,428.01
in general payments reported to CMS, 2019-2025
28 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $233 · 2021: $170 · 2022: $4,431 · 2023: $6,853 · 2024: $278 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,020 · Food and Beverage: $1,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,020.00 |
| Food and Beverage | $1,295.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,696.62 | 2019-2024 | Davinci Xi, Da Vinci Surgical System |
| Ethicon US, LLC | $284.10 | 2019-2025 | Vistaseal, Ethicon, Stratafix |
| Karl Storz Endoscopy-America | $167.66 | 2023 | Image1 S Connect |
| Davol INC. | $159.88 | 2020-2023 | Phasix Mesh |
| Boston Scientific Corporation | $151.49 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $123.19 | 2021-2022 | |
| Polynovo North America LLC | $110.72 | 2023 | |
| Covidien LP | $73.86 | 2019 | |
| Medtronic, INC. | $71.55 | 2021-2022 | |
| Abbvie INC. | $60.00 | 2023-2025 | |
| Lemaitre Vascular, INC. | $56.06 | 2019 | |
| Chiesi USA, INC. | $51.38 | 2022-2023 | Cleviprex |
| Stryker Corporation | $47.53 | 2023 | Spy-Phi System |
| Csl Behring | $46.76 | 2024 | Kcentra |
| Tela Bio, INC. | $40.43 | 2020-2024 | Ovitex 2s |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $34.27 | 2024 | Gore Enform Preperitoneal Biomaterial |
| Merck Sharp & Dohme LLC | $31.49 | 2020-2025 | Keytruda |
| Integra Lifesciences Corporation | $29.64 | 2021-2022 | |
| Amgen INC. | $27.31 | 2025 | Tepezza |
| Takeda Pharmaceuticals U.S.A., INC. | $23.74 | 2020-2021 | |
| Bard Peripheral Vascular, INC. | $23.67 | 2025 | Lutonix Drug Coated Balloon |
| Abbott Laboratories | $22.79 | 2024 | Diamondback Peripheral |
| Phathom Pharmaceuticals, INC. | $21.04 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $17.39 | 2019 | |
| Olympus America INC. | $15.74 | 2023 | 4k Cable 8.5m |
| Solventum Corporation | $14.83 | 2025 | Activ.A.C. |
| Braintree Laboratories, INC. | $13.79 | 2023 | Sutab |
| Cook Medical LLC | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Falcone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.